AOD-9604 in Canada: A Research Guide to the hGH Lipolytic Fragment

Why AOD-9604 deserves a dedicated weight-management guide#

AOD-9604 Canada searches come from a specific corner of the peptide research market. The compound is not a GLP-1 receptor agonist like Semaglutide or Tirzepatide. It is not a dual or triple incretin like Retatrutide. It is a fragment peptide derived from human growth hormone, developed two decades before the current GLP-1 wave, with a mechanism that targets adipose tissue lipolysis rather than appetite suppression or gastric emptying. That difference matters for research design, and it is why AOD-9604 needs its own guide rather than being lumped into a generic "weight-loss peptide" list.

Northern Compound places AOD-9604 in the weight-management archive because the search intent is clearly metabolic: researchers are looking for compounds that influence fat oxidation, adipocyte biology, or body-composition endpoints. But the responsible framing is not promotional. AOD-9604 has a real preclinical literature, a completed human safety database, and a terminated Phase IIb programme. A good research guide should explain what the compound is, what the strongest studies show, where the clinical development failed, how it differs from intact hGH and from modern incretin agonists, and what a Canadian lab should verify before using it.

This article treats AOD-9604 as research-use-only material. It does not provide dosing instructions, injection guidance, obesity-treatment advice, or personal-use recommendations. The narrower and more useful purpose is to map the evidence, clarify the mechanism, and set sourcing standards that match the compound's actual research history.

What AOD-9604 is at the molecular level#

AOD-9604 is the synthetic peptide Tyr-hGH(177-191), a 16-amino-acid sequence derived from the C-terminus of human growth hormone. The full sequence is:

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

This corresponds to residues 177 through 191 of the 191-amino-acid hGH polypeptide, with an N-terminal tyrosine added to the fragment for synthetic or analytical convenience in some preparations. The molecular weight is approximately 1817 Da, and the peptide contains a single intramolecular disulfide bridge between Cys residues at positions 7 and 13 of the fragment (equivalent to Cys183 and Cys189 in the full hGH sequence).

The peptide was originally synthesised and characterised by researchers at Metabolic Pharmaceuticals in Melbourne, Australia, who hypothesised that the lipolytic effects of hGH could be localised to a specific domain separate from the growth-promoting and insulin-antagonistic effects mediated by the full protein. The rationale was elegant: if fat metabolism could be decoupled from IGF-1 stimulation, bone growth, and glucose dysregulation, the resulting compound might offer a safer profile for anti-obesity research than intact hGH.

For analytical verification, AOD-9604 should be treated as a standard synthetic peptide. The minimum supplier package includes:

1. Batch-specific HPLC purity with peak integration, method conditions, and lot number.
2. Mass spectrometry identity confirmation showing the expected molecular ion at approximately 1817 Da.
3. Sequence confirmation by tandem MS or Edman degradation where available.
4. Disulfide-bond verification because the Cys7-Cys13 bridge is structurally important; some suppliers report this by peptide mapping or by comparing reduced versus non-reduced MS profiles.
5. Fill amount and counter-ion documentation stating the actual peptide content per vial, not just the total lyophilisate mass.
6. Storage guidance appropriate for a disulfide-containing peptide: typically lyophilised, protected from light, and stored at -20 °C or below.

Researchers should not accept a vial labelled simply "hGH fragment" without sequence specification. The hGH fragment nomenclature is imprecise, and other fragments (such as 176-191 or truncated variants) may circulate in grey-market catalogues under similar names. The exact sequence, disulfide status, and analytical package determine whether the material is actually AOD-9604.

Mechanism: lipolysis without IGF-1 elevation#

The central mechanistic claim for AOD-9604 is that it stimulates lipolysis and fat oxidation in adipose tissue without triggering the systemic growth-promoting and diabetogenic effects of full-length hGH. That claim is supported by preclinical data and is the defining feature that separates AOD-9604 from both recombinant hGH and from GH-secretagogue peptides such as MK-677 or Ipamorelin.

Beta-3-adrenergic receptor signalling#

The strongest mechanistic evidence points to beta-3-adrenergic-receptor (β3-AR) activation in adipocytes. In obese mice, chronic AOD-9604 administration increases lipolytic sensitivity and fat oxidation, and these effects correlate with increased β3-AR RNA expression in adipose tissue. The β3-AR is the predominant adrenergic receptor subtype in white and brown adipose tissue in rodents, and its activation triggers cyclic-AMP-mediated hormone-sensitive lipase activation, leading to triglyceride hydrolysis and free fatty acid release.

However, the mechanism is not exclusively β3-AR-dependent. Heffernan and colleagues (2001) showed that AOD-9604 still increased energy expenditure and fat oxidation in β3-AR knockout mice, although the magnitude of the effect was reduced. That finding implies either partial β3-AR independence, compensatory pathways, or effects on other tissues such as skeletal muscle or liver that contribute to the overall metabolic phenotype. For research design, the implication is that AOD-9604 protocols should measure multiple endpoints, not just adipose β3-AR expression.

Distinction from hGH receptor signalling#

AOD-9604 is not a high-affinity agonist of the full-length hGH receptor. It does not stimulate IGF-1 production in the systems tested, and it does not produce the insulin-antagonistic effects characteristic of pharmacological hGH dosing. That separation is pharmacologically important. Full-length hGH raises fasting glucose, reduces insulin sensitivity, and carries long-term theoretical risks related to IGF-1-mediated cell proliferation. AOD-9604 was designed to avoid those liabilities, and the preclinical data generally support that separation, though the human clinical data are too limited to draw definitive metabolic-safety conclusions.

Comparison with incretin-based mechanisms#

Modern weight-management research is dominated by GLP-1, GIP, and glucagon receptor agonism. Semaglutide and tirzepatide work primarily through appetite suppression, delayed gastric emptying, and central satiety signalling. AOD-9604 does not act on the incretin axis. It does not stimulate insulin secretion in a glucose-dependent manner, and it does not bind the GLP-1 receptor. For researchers comparing peptide approaches to body-composition modulation, that mechanistic chasm is more important than any surface similarity in catalogue category.

Preclinical evidence in obesity and metabolism models#

The preclinical literature on AOD-9604 is more developed than that of many research peptides, partly because the compound was backed by a pharmaceutical company with dedicated development resources.

Murine obesity studies#

Heffernan et al. (2001), published in Endocrinology, is the foundational preclinical paper. The researchers treated obese mice with chronic intraperitoneal AOD-9604 for 14 days and observed reduced body weight and body fat compared with vehicle-treated controls. The effect was dose-dependent and correlated with increased lipolytic sensitivity in isolated adipocytes. Importantly, the study also included β3-AR knockout mice, which showed attenuated but not abolished responses, supporting a partial β3-AR mechanism.

A separate study in Journal of Bone and Mineral Research examined whether AOD-9604 affected bone metabolism. The rationale was that hGH has anabolic effects on bone through IGF-1, and removing that axis might eliminate bone benefits. The data showed that AOD-9604 did not produce the bone-remodelling markers seen with full-length hGH, confirming the desired separation of lipolytic from osteotropic effects.

Safety pharmacology and toxicology#

Metabolic Pharmaceuticals conducted a comprehensive non-clinical safety package, later summarised by Moré and Kenley (2014) in the Journal of Endocrinology and Metabolism. Key studies included:

• Ames test: Negative for mutagenicity in Salmonella typhimurium and E. coli strains at doses up to 2,000 µg/plate, with and without metabolic activation.
• In vitro chromosome aberration: Negative in Chinese hamster ovary cells at doses up to 1,000 µg/mL.
• Bone-marrow micronucleus: No clear dose-response relationship in rats; slight increases at some doses were not considered biologically significant.
• 4-week intravenous toxicity in rats: No treatment-related deaths or clinical signs. Reduced body-mass gain in females at 1.0 and 10.0 mg/kg/day. Reduced thymus mass in males at the highest dose.
• 6-month oral gavage in rats: NOAEL of at least 100 mg/kg/day, the highest dose tested.
• 9-month oral gavage in cynomolgus monkeys: No adverse findings at doses up to 50 mg/kg/day.

These data supported the conclusion that AOD-9604 carried no genotoxic concerns and was well tolerated in repeat-dose studies at high multiples of projected human exposure. For researchers, the toxicology package is useful background, but it does not translate into a licence for human self-administration or therapeutic use outside regulated clinical trials.

Human clinical trials: from Phase I to termination#

AOD-9604 is one of the few research peptides with a published human clinical trial history that includes Phase I, Phase II, and Phase IIb studies. That history is instructive because it shows both the potential and the limits of the compound.

Early-phase safety and metabolism#

Six human clinical trials (intravenous and oral) were completed before 2007. The Phase I data showed that AOD-9604 was safe and well tolerated, with no significant adverse effects on cardiovascular, hepatic, renal, or haematological parameters. Oral bioavailability was sufficient to support tablet formulation, and the pharmacokinetic profile was consistent with a small peptide subject to peptidase degradation but still capable of partial systemic absorption.

Phase II efficacy signals#

A Phase II trial without formal diet-and-exercise counselling produced average weight loss greater than placebo across multiple dose groups at 12 weeks. The 1 mg/day oral dose produced the strongest signal, falling just short of statistical significance on the primary analysis (p = 0.1) but reaching significance in a female subgroup. The effect size was approximately 2 kg greater than placebo over 12 weeks, accompanied by modest improvements in lipid profiles. These results were encouraging enough to warrant a larger, more rigorous Phase IIb study.

Phase IIb OPTIONS Study and its failure#

The OPTIONS Study was designed to be predictive of Phase III outcomes. It enrolled 536 subjects (approximately equal men and women) across 16 Australian clinical sites, with BMI 30–45 kg/m² and waist-circumference criteria. After a four-week single-blind placebo run-in with diet-and-exercise counselling, subjects were randomised to placebo, 0.25 mg, 0.5 mg, or 1.0 mg AOD-9604 orally once daily for 24 weeks. The primary endpoint was weight loss at 12 weeks.

The trial was powered for an 80 percent chance of detecting significance if the active group lost 1.8 kg more than placebo. The results, announced in February 2007, showed that weight loss versus placebo was too low to reach statistical significance at any dose. Under Phase-3-like conditions, with formal lifestyle intervention, AOD-9604 did not demonstrate the efficacy required for commercial viability as an obesity treatment. Metabolic Pharmaceuticals terminated the obesity programme on the same day.

The failure is scientifically important. It suggests that AOD-9604's lipolytic mechanism, while detectable in preclinical models and in less-controlled early human studies, was not robust enough to produce clinically meaningful weight loss when combined with the standard-of-care diet-and-exercise programme that regulatory authorities and reimbursement bodies expect. The company's own conclusion was that AOD-9604 "does not combine or synergise with successful use of an ongoing diet and exercise programme, but may show some effect with moderate weight loss effort in females."

For researchers, the OPTIONS Study is a cautionary example of how preclinical and early-phase signals can attenuate in larger, better-controlled trials. It also underscores that a compound's research interest is not synonymous with therapeutic efficacy.

Metabolic distinctions: AOD-9604 versus intact hGH and GH secretagogues#

Canadian researchers often encounter AOD-9604 in catalogues that also list growth-hormone peptides, GH secretagogues, and metabolic compounds. Understanding where AOD-9604 fits requires comparing it with its nearest mechanistic neighbours.

This table highlights why AOD-9604 should not be treated as a "milder hGH" or as a substitute for GH secretagogues in research protocols. The receptor biology, downstream signalling, and risk profile are distinct.

WADA status and regulatory framing#

AOD-9604 occupies a complicated regulatory position. It is explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List under the category S0 (Non-Approved Substances), with the specific example "growth hormone fragments, e.g. AOD-9604." WADA's 2013 statement clarified that the substance falls under S0 because it has no current approval by any governmental regulatory health authority for human therapeutic use.

The WADA listing matters for Canadian researchers in two ways. First, if the research programme involves any athlete-subjects or sports-performance endpoints, AOD-9604 is prohibited at all times and its presence in samples would constitute an anti-doping violation. Second, the WADA classification signals that major regulatory bodies consider the compound pharmacologically active and potentially performance-relevant, even if its clinical efficacy for obesity was insufficient.

Health Canada has not approved AOD-9604 for any therapeutic indication. The FDA has not approved it. The EMA has not approved it. No major jurisdiction has granted marketing authorisation. Research material sold in Canada must therefore be explicitly labelled research-use-only, and suppliers should avoid any language that implies therapeutic or cosmetic approval.

Canadian RUO context and compliance language#

For Canadian labs, the regulatory landscape for AOD-9604 is straightforward in principle but often blurred in practice. The compound is not a Health Canada-approved drug. It is not a natural health product. It is not a veterinary medicine with off-label human relevance. It is a synthetic peptide with a terminated clinical development programme and a WADA prohibition.

Research-use-only means laboratory research. It does not mean personal experimentation, gym use, or cosmetic self-administration. Canadian researchers should expect suppliers to:

• Label the product explicitly as research-use-only.
• Avoid therapeutic claims, dosing instructions, or human-use guidance.
• Provide batch-specific analytical documentation.
• Ship with appropriate stability and storage instructions.
• Include a safety data sheet (SDS) for laboratory handling.

Northern Compound's broader Canadian research peptide buyer's guide covers supplier evaluation in detail. For AOD-9604 specifically, the due-diligence checklist should emphasise sequence verification and disulfide-bond confirmation, because fragment peptides are more susceptible to synthesis errors, truncated sequences, and misfolded variants than simple linear peptides.

Sourcing AOD-9604: COA, purity, and analytical expectations#

Because AOD-9604 is a synthetic peptide with a defined sequence and a structurally important disulfide bond, its analytical requirements are slightly more demanding than those of a simple linear peptide.

Minimum COA expectations#

1. HPLC purity: A reversed-phase chromatogram showing the principal peak, integration percentage, method conditions, and lot number. Purity should be reported as the peptide peak area percentage, with clear identification of any significant impurities.
2. Mass spectrometry: Electrospray ionisation MS or MALDI-TOF confirming the expected molecular weight of approximately 1817 Da. If the material is supplied as a salt, the COA should specify the counter-ion and the corresponding molecular weight.
3. Disulfide-bond confirmation: Because the Cys7-Cys13 bridge is part of the designed structure, the supplier should provide evidence that the bridge is intact. This can be done by comparing reduced and non-reduced MS profiles, by peptide mapping after enzymatic digestion, or by an explicit statement in the analytical report.
4. Sequence verification: Tandem MS (MS/MS) or Edman degradation data confirming the exact amino-acid sequence, including the N-terminal Tyr.
5. Fill amount: The vial should state the net peptide content, not just the total mass of lyophilised powder. Excipients such as mannitol or acetic acid should be listed if present.
6. Residual solvent and water content: Particularly for peptides manufactured by solid-phase synthesis, residual TFA, acetonitrile, or ether levels should be within acceptable limits.
7. Storage and stability data: Guidance on reconstitution, shelf life, and recommended storage temperature.

Supplier red flags#

• A product labelled only "hGH fragment" without sequence specification.
• A COA that reports only total lyophilisate mass, not net peptide content.
• Absence of mass spectrometry or sequence data.
• Claims about fat loss, muscle gain, or cosmetic results on the product page.
• Pricing or packaging oriented toward consumer rather than laboratory use.

Lynx Labs lists AOD-9604 in the weight-management category and is the domestic supplier Northern Compound currently points readers toward for Canadian research-source evaluation. That recommendation is based on the same criteria applied elsewhere: batch documentation, domestic fulfilment, product-category clarity, and attribution-transparent outbound links. Researchers should still verify the current lot's COA before using any material in an experiment.

Comparison with modern weight-management peptides#

AOD-9604 is frequently compared with GLP-1-based compounds in online discussions, but the comparison is mechanistically weak. The table below clarifies the research positioning.

For Canadian researchers designing body-composition studies, the choice between AOD-9604 and a GLP-1 agonist should be driven by the experimental question, not by catalogue convenience. AOD-9604 is relevant for adipose-tissue-specific mechanisms, beta-3-AR biology, and historical anti-obesity peptide development. GLP-1 agonists are relevant for neuroendocrine appetite regulation, incretin physiology, and metabolic disease models.

Designing better AOD-9604 studies#

A high-quality AOD-9604 study should exploit the compound's specific features rather than treating it as a generic "fat-loss peptide." Because the clinical development programme is terminated, there is no pending regulatory filing to align with, and researchers have more freedom to explore mechanistic questions.

Adipose-tissue mechanistic studies#

The beta-3-AR partial dependence observed in knockout mice suggests that AOD-9604 research should include adipose-tissue endpoints: lipolysis rates in isolated adipocytes, hormone-sensitive lipase phosphorylation, cyclic-AMP levels, and beta-3-AR expression. A study that measures only body weight misses the mechanistic layer.

Comparative designs#

A strong protocol would compare AOD-9604 with a selective beta-3-agonist (where available) and with vehicle in a diet-induced obesity model. The hypothesis would be whether AOD-9604's effects are entirely beta-3-mediated or whether additional pathways contribute. A second comparator arm might use intact hGH at a low dose to confirm the desired separation of lipolytic from growth-promoting effects.

Metabolic safety monitoring#

Although AOD-9604 was designed to avoid hGH-like metabolic liabilities, any compound that influences adipose lipolysis can theoretically affect circulating free fatty acids, hepatic lipid metabolism, and insulin sensitivity. A comprehensive protocol includes fasting glucose, insulin, HOMA-IR, lipid panels, and possibly clamp-derived insulin sensitivity at baseline and follow-up.

Female-specific endpoints#

The Phase II female subgroup showed a stronger signal than the overall population. If the preclinical literature supports sex-specific differences in beta-3-AR expression or adipose biology, a well-designed study might stratify by sex or use ovariectomised models to examine hormonal modulation.

Common mistakes in AOD-9604 interpretation#

The first mistake is treating AOD-9604 as a "safe hGH alternative" for muscle building or anti-ageing. The compound does not stimulate IGF-1, does not produce hGH-like anabolic effects, and was never developed for those indications. Its research identity is adipose-tissue lipolysis, not systemic growth promotion.

The second mistake is assuming that preclinical weight-loss data in mice translate directly to human efficacy. The OPTIONS Study showed that even a well-funded, well-designed Phase IIb trial can fail when preclinical signals attenuate under rigorous conditions.

The third mistake is conflating "no significant safety findings in trials" with "safe for any use." The clinical database is limited to several hundred subjects over 12–24 weeks. Long-term safety, interactions, and effects in metabolically compromised populations are not well characterised.

The fourth mistake is ignoring the WADA prohibition. Researchers working with athletic populations, sports-science departments, or performance-oriented endpoints must account for the fact that AOD-9604 is banned at all times under the S0 category.

The fifth mistake is using product-page copy as a primary literature source. Supplier descriptions may cite the Heffernan study or the Phase II data without explaining the termination of the obesity programme. Researchers should read the original papers and the ASX/SEC filings.

The sixth mistake is accepting material labelled only "hGH fragment" without sequence confirmation. Synthetic peptide fragments are susceptible to truncation, oxidation, and disulfide scrambling. A COA that skips sequence or disulfide verification is insufficient.

References and further reading#

• Heffernan M. et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice." Endocrinology (2001). PubMed.
• Moré M.I., Kenley D. "Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health." Journal of Endocrinology and Metabolism (2014). DOI.
• Metabolic Pharmaceuticals Limited. "Obesity Drug – Phase 2b Clinical Trial Results." ASX Announcement, 21 February 2007. SEC Filing.
• Valentino M.A., Lin J.E., Waldman S.A. "Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy." Clinical Pharmacology & Therapeutics (2010). PMC.
• World Anti-Doping Agency. "WADA statement on substance AOD-9604." 22 April 2013. WADA.
• World Anti-Doping Agency. Prohibited List. Current edition. WADA.
• Metabolic Pharmaceuticals Limited. "First 100 Subjects Complete The Phase 2B Trial Of AOD9604." BioSpace, 5 October 2006. BioSpace.